Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses.
| Title: | Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses. |
|---|---|
| Authors: | Pelissier Vatter FA; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.; Cioffi M; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.; Hanna SJ; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.; Castarede I; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.; Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Caielli S; Drukier Institute for Children's Health and Department of Pediatrics, Weill Cornell Medicine, New York, NY.; Pascual V; Drukier Institute for Children's Health and Department of Pediatrics, Weill Cornell Medicine, New York, NY.; Matei I; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY.; Lyden D; Children's Cancer and Blood Foundation Laboratories, Departments of Pediatrics and Cell and Developmental Biology, Drukier Institute for Children's Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY. |
| Source: | The Journal of experimental medicine [J Exp Med] 2021 Aug 02; Vol. 218 (8). Date of Electronic Publication: 2021 Jun 28. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
| Language: | English |
| Journal Info: | Publisher: Rockefeller University Press Country of Publication: United States NLM ID: 2985109R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-9538 (Electronic) Linking ISSN: 00221007 NLM ISO Abbreviation: J Exp Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: New York, NY : Rockefeller University Press |
| MeSH Terms: | Adaptive Immunity* ; Immunity, Innate*; Cell Communication/*immunology ; Cell-Derived Microparticles/*immunology ; Extracellular Vesicles/*immunology; Animals ; Humans ; Immunotherapy |
| Abstract: | Intercellular communication among immune cells is vital for the coordination of proper immune responses. Extracellular vesicles and particles (EVPs) act as messengers in intercellular communication, with important consequences for target cell and organ physiology in both health and disease. Under normal physiological conditions, immune cell-derived EVPs participate in immune responses by regulating innate and adaptive immune responses. EVPs play a major role in antigen presentation and immune activation. On the other hand, immune cell-derived EVPs exert immunosuppressive and regulatory effects. Consequently, EVPs may contribute to pathological conditions, such as autoimmune and inflammatory diseases, graft rejection, and cancer progression and metastasis. Here, we provide an overview of the role of EVPs in immune homeostasis and pathophysiology, with a particular focus on their contribution to innate and adaptive immunity and their potential use for immunotherapies.; (© 2021 Pelissier Vatter et al.) |
| Competing Interests: | Disclosures: The authors declare no competing interests exist. |
| References: | J Biol Chem. 2003 Mar 28;278(13):10963-72. (PMID: 12519789); Int Rev Cell Mol Biol. 2019;349:213-249. (PMID: 31759432); Nature. 2014 Mar 6;507(7490):118-23. (PMID: 24487619); Theranostics. 2017 Jul 7;7(10):2732-2745. (PMID: 28819459); J Extracell Vesicles. 2015 Jul 02;4:28239. (PMID: 26142461); Int J Mol Sci. 2020 Oct 04;21(19):. (PMID: 33020408); J Biol Chem. 2007 Aug 31;282(35):25779-89. (PMID: 17591775); Blood Cells Mol Dis. 2005 Jul-Aug;35(1):17-20. (PMID: 15932799); Nat Rev Immunol. 2014 Mar;14(3):195-208. (PMID: 24566916); J Immunol. 2009 Aug 1;183(3):1884-91. (PMID: 19596992); Leukemia. 2018 Mar;32(3):575-587. (PMID: 28816238); Nat Rev Immunol. 2002 Aug;2(8):569-79. (PMID: 12154376); Mol Ther. 2006 Feb;13(2):289-300. (PMID: 16275099); Autoimmunity. 2014 Jun;47(4):272-85. (PMID: 24826805); Cell Rep. 2019 Apr 16;27(3):940-954.e6. (PMID: 30956133); Theranostics. 2017 Jan 1;7(1):81-96. (PMID: 28042318); Nat Cell Biol. 2018 Mar;20(3):228-230. (PMID: 29476154); Eur J Immunol. 2006 Jul;36(7):1772-81. (PMID: 16761310); J Immunol. 2018 Jan 15;200(2):422-431. (PMID: 29311384); Cell. 1998 Sep 4;94(5):667-77. (PMID: 9741631); Proc Natl Acad Sci U S A. 1978 Oct;75(10):5132-6. (PMID: 154105); J Immunol. 2005 May 15;174(10):6440-8. (PMID: 15879146); J Transl Med. 2005 Mar 02;3(1):10. (PMID: 15740633); J Transl Med. 2005 Feb 21;3(1):9. (PMID: 15723705); Trends Cell Biol. 2009 Feb;19(2):43-51. (PMID: 19144520); J Immunol. 2004 Feb 15;172(4):2126-36. (PMID: 14764678); J Immunol. 2007 Aug 1;179(3):1489-96. (PMID: 17641014); Cell Metab. 2018 Jan 9;27(1):237-251.e4. (PMID: 29320704); PLoS One. 2016 Mar 14;11(3):e0151339. (PMID: 26974972); Allergy. 2015 Dec;70(12):1651-5. (PMID: 26198793); Blood. 2007 May 1;109(9):3856-64. (PMID: 17192399); Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075); Int J Biol Macromol. 2018 Jul 1;113:1182-1187. (PMID: 29427678); Haematologica. 2012 Jun;97(6):818-26. (PMID: 22271895); Nat Rev Immunol. 2020 Feb;20(2):75-76. (PMID: 31925406); Eur J Immunol. 2018 Nov;48(11):1915-1917. (PMID: 30207595); Science. 2008 Feb 29;319(5867):1244-7. (PMID: 18309083); Exp Mol Med. 2019 Aug 9;51(8):1-13. (PMID: 31399559); Front Immunol. 2018 Apr 11;9:721. (PMID: 29696020); Gastroenterology. 2007 May;132(5):1866-76. (PMID: 17484880); Cell. 2019 Jan 10;176(1-2):113-126.e15. (PMID: 30633902); Front Cell Dev Biol. 2021 Feb 05;9:634853. (PMID: 33614663); Nat Med. 1998 May;4(5):594-600. (PMID: 9585234); J Hepatol. 2017 Oct;67(4):739-748. (PMID: 28549917); J Immunol. 2007 Oct 15;179(8):5523-33. (PMID: 17911639); Int J Nanomedicine. 2019 Nov 13;14:8875-8889. (PMID: 32009785); Nanoscale. 2020 May 21;12(19):10854-10862. (PMID: 32396590); J Immunol. 2000 Jan 1;164(1):161-7. (PMID: 10605007); Nature. 1998 Sep 3;395(6697):82-6. (PMID: 9738502); J Clin Invest. 2016 Apr 1;126(4):1224-32. (PMID: 27035813); Nat Rev Immunol. 2014 May;14(5):329-42. (PMID: 24751956); J Immunol. 2000 Aug 1;165(3):1259-65. (PMID: 10903724); Ann Transl Med. 2017 Apr;5(7):172. (PMID: 28480208); Am J Transplant. 2006 Jul;6(7):1541-50. (PMID: 16827854); Nat Biotechnol. 2011 Apr;29(4):341-5. (PMID: 21423189); Nat Protoc. 2019 Apr;14(4):1027-1053. (PMID: 30833697); Nature. 2014 Jan 16;505(7483):327-34. (PMID: 24429631); EMBO J. 2007 Oct 3;26(19):4263-72. (PMID: 17805347); Nat Cell Biol. 2018 Mar;20(3):332-343. (PMID: 29459780); Nat Commun. 2015 Jun 18;6:7321. (PMID: 26084661); Cell. 2019 Apr 4;177(2):428-445.e18. (PMID: 30951670); J Immunol. 1999 Nov 15;163(10):5201-10. (PMID: 10553040); J Extracell Vesicles. 2019 Nov 8;8(1):1688936. (PMID: 31762964); Cell Death Dis. 2020 Jul 30;11(7):603. (PMID: 32733020); Biomed Res Int. 2019 May 15;2019:6387924. (PMID: 31223621); Haematologica. 2018 Mar;103(3):382-394. (PMID: 29439185); PLoS One. 2015 Sep 21;10(9):e0138618. (PMID: 26390437); Nature. 2018 Aug;560(7718):382-386. (PMID: 30089911); Cancer Res. 2013 Jul 1;73(13):3865-76. (PMID: 23658368); Cell Res. 2014 Jun;24(6):766-9. (PMID: 24710597); Nature. 2015 Nov 19;527(7578):329-35. (PMID: 26524530); J Immunol Methods. 2002 Dec 15;270(2):211-26. (PMID: 12379326); J Immunol. 2007 Aug 15;179(4):2242-9. (PMID: 17675485); Eur J Immunol. 1999 Apr;29(4):1363-73. (PMID: 10229104); Science. 2020 Feb 7;367(6478):. (PMID: 32029601); J Extracell Vesicles. 2019 May 28;8(1):1615820. (PMID: 31191831); Sci Rep. 2018 Jul 9;8(1):10340. (PMID: 29985427); J Immunol. 1985 Aug;135(2 Suppl):739s-742s. (PMID: 3159798); Biochem J. 2004 May 15;380(Pt 1):161-71. (PMID: 14965343); Cancers (Basel). 2019 Oct 14;11(10):. (PMID: 31615107); Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228. (PMID: 29339798); Circ Res. 2017 Apr 28;120(9):1466-1476. (PMID: 28298297); J Cell Biol. 1983 Aug;97(2):329-39. (PMID: 6309857); Int Immunol. 1999 Nov;11(11):1739-44. (PMID: 10545477); Nanomedicine. 2018 Jan;14(1):195-204. (PMID: 28982587); Nephrol Dial Transplant. 2015 Sep;30(9):1488-96. (PMID: 26040904); J Immunol. 2012 Sep 15;189(6):2833-42. (PMID: 22904309); Proteomics. 2016 Apr;16(7):1131-45. (PMID: 26806198); Oncoimmunology. 2015 Aug 12;5(4):e1071008. (PMID: 27141373); J Cell Biol. 1985 Sep;101(3):942-8. (PMID: 2993317); Int J Mol Sci. 2020 Mar 01;21(5):. (PMID: 32121610); Nat Rev Rheumatol. 2014 Jun;10(6):356-64. (PMID: 24535546); Blood. 2008 May 15;111(10):5028-36. (PMID: 18198347); Adv Drug Deliv Rev. 2013 Mar;65(3):336-41. (PMID: 22780955); Nat Cell Biol. 2007 Jun;9(6):654-9. (PMID: 17486113); Mol Cancer. 2019 Oct 23;18(1):146. (PMID: 31647023); J Surg Res. 2011 Dec;171(2):826-32. (PMID: 20828738); Nanomedicine. 2016 Apr;12(3):655-664. (PMID: 26586551); Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33. (PMID: 20304794); J Proteomics. 2012 Dec 5;76 Spec No.:287-96. (PMID: 22415276); J Immunol. 2010 Oct 1;185(7):4206-12. (PMID: 20810987); Blood. 2009 Jan 29;113(5):1112-21. (PMID: 18802008); Nat Cell Biol. 2019 Jul;21(7):856-866. (PMID: 31235936); J Neuroimmunol. 2014 Jan 15;266(1-2):12-23. (PMID: 24275061); Blood. 1999 Dec 1;94(11):3791-9. (PMID: 10572093); Acta Pharm Sin B. 2016 Jul;6(4):287-96. (PMID: 27471669); Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77. (PMID: 26858453); Sci Rep. 2018 Jun 12;8(1):8973. (PMID: 29895824); Immunity. 2019 Apr 16;50(4):924-940. (PMID: 30995507); J Proteome Res. 2017 Jan 6;16(1):238-246. (PMID: 27728760); Blood Cells Mol Dis. 2005 Sep-Oct;35(2):158-68. (PMID: 16087368); FASEB J. 2003 Mar;17(3):476-8. (PMID: 12514112); Glia. 2013 Jul;61(7):1003-17. (PMID: 23625857); Nat Med. 2011 Mar;17(3):320-9. (PMID: 21383745); Immunol Rev. 2013 Jan;251(1):65-79. (PMID: 23278741); J Neurochem. 2016 Jan;136 Suppl 1:39-48. (PMID: 25628216); J Immunol. 2008 Mar 1;180(5):3081-90. (PMID: 18292531); Eur J Immunol. 2012 Dec;42(12):3334-45. (PMID: 22996386); Anal Chem. 2018 Jul 17;90(14):8314-8319. (PMID: 29920066); PLoS One. 2014 Oct 17;9(10):e110383. (PMID: 25329154); Leukemia. 2006 May;20(5):847-56. (PMID: 16453000); Biomaterials. 2014 Feb;35(7):2383-90. (PMID: 24345736); J Drug Deliv. 2013;2013:516749. (PMID: 23781340); Arthritis Res Ther. 2016 Nov 16;18(1):264. (PMID: 27852323); Cytometry A. 2007 Jan;71(1):38-45. (PMID: 17216623); J Clin Invest. 2016 Dec 1;126(12):4537-4553. (PMID: 27797340); Nat Commun. 2018 Jan 2;9(1):17. (PMID: 29295981); Nat Immunol. 2018 Feb;19(2):108-119. (PMID: 29348500); Nat Cell Biol. 2019 Jan;21(1):9-17. (PMID: 30602770); Dev Cell. 2019 May 6;49(3):347-360. (PMID: 31063754); J Immunol. 2017 Oct 1;199(7):2225-2235. (PMID: 28842467); Cell. 2016 Jun 30;166(1):88-101. (PMID: 27293190); Arthritis Rheum. 2006 Dec;54(12):3809-14. (PMID: 17133577); Sci Rep. 2015 Dec 03;5:17622. (PMID: 26631690); Arthritis Rheum. 2005 May;52(5):1517-21. (PMID: 15880835); Cell. 2020 Aug 20;182(4):1044-1061.e18. (PMID: 32795414); Sci Rep. 2018 Apr 17;8(1):6065. (PMID: 29666503); Annu Rev Immunol. 2000;18:767-811. (PMID: 10837075); Eur J Immunol. 2003 Feb;33(2):522-31. (PMID: 12645951); Traffic. 2009 Oct;10(10):1528-42. (PMID: 19682328); Diabetes. 2018 Aug;67(8):1639-1649. (PMID: 29866771); J Exp Med. 1996 Mar 1;183(3):1161-72. (PMID: 8642258); FASEB J. 2012 Jul;26(7):3084-95. (PMID: 22505472); Blood. 2001 Sep 1;98(5):1289-97. (PMID: 11520773); J Biomed Sci. 2020 Mar 23;27(1):45. (PMID: 32200762); Trends Mol Med. 2019 May;25(5):382-394. (PMID: 30853173); Immunity. 2014 Jul 17;41(1):89-103. (PMID: 25035954); Biol Cell. 2006 Aug;98(8):491-501. (PMID: 16677129); Eur J Immunol. 1998 May;28(5):1636-44. (PMID: 9603470); J Neuroinflammation. 2018 Aug 27;15(1):239. (PMID: 30149804); J Cell Biol. 1999 Nov 1;147(3):599-610. (PMID: 10545503); Immunol Rev. 2013 May;253(1):146-57. (PMID: 23550644); Annu Rev Immunol. 2018 Apr 26;36:435-459. (PMID: 29400984); Nat Rev Cancer. 2017 May;17(5):302-317. (PMID: 28303905); Nat Commun. 2017 Nov 6;8(1):1319. (PMID: 29105655); Semin Cell Dev Biol. 2017 Jul;67:65-73. (PMID: 28189858); Immunity. 2017 Jul 18;47(1):51-65.e7. (PMID: 28666573); Cell. 2019 Apr 4;177(2):414-427.e13. (PMID: 30951669); Leukemia. 2006 Sep;20(9):1487-95. (PMID: 16791265); J Immunol. 2010 Nov 1;185(9):5268-78. (PMID: 20881190); J Cell Sci. 2000 Oct;113 Pt 19:3365-74. (PMID: 10984428); Scand J Gastroenterol. 2010 Oct;45(10):1168-77. (PMID: 20469967); Trends Biotechnol. 2021 Jun;39(6):598-612. (PMID: 33160678); J Cell Sci. 2019 Oct 15;132(20):. (PMID: 31615844); J Immunol. 2009 Feb 1;182(3):1548-59. (PMID: 19155503); Aging (Albany NY). 2019 Oct 26;11(20):8911-8924. (PMID: 31655796); Front Pediatr. 2018 May 23;6:142. (PMID: 29876337); Front Endocrinol (Lausanne). 2017 Aug 08;8:194. (PMID: 28848498) |
| Grant Information: | U54 CA163117 United States CA NCI NIH HHS; R01 CA218513 United States CA NCI NIH HHS; U19 AI144301 United States AI NIAID NIH HHS; K00 CA212451 United States CA NCI NIH HHS; R01 CA207983 United States CA NCI NIH HHS; P2SKP3 174785 Switzerland SNSF_ Swiss National Science Foundation; U54 CA163120 United States CA NCI NIH HHS; U01 CA224175 United States CA NCI NIH HHS; U01 CA210240 United States CA NCI NIH HHS; NCI CA224175 United States NH NIH HHS; R35 CA232093 United States CA NCI NIH HHS |
| Entry Date(s): | Date Created: 20210628 Date Completed: 20211102 Latest Revision: 20220204 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8241538 |
| DOI: | 10.1084/jem.20202579 |
| PMID: | 34180950 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review